Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

Inclusion Criteria * Suspected or confirmed Methicillin-resistant Staphylococcus aureus (MRSA) infection * Japanese Male and female patients aged 18 years or above * Diagnosis of Skin and soft tissue infection with MRSA either suspected or confirmed as the major cause of infection, with/without SSTI (skin and soft tissue infection)-derived MRSA bacteremia suspected Exclusion Criteria: * Having received any systemic antibacterial potentially effective against MRSA for \>/=24 hours within 3 days prior to the first infusion of a study drug, or having received/expected to receive the medication within 24 hours prior to the first infusion, unless antibacterial therapy for \>/=72 hours proves to be ineffective on or lack appropriate potency (resistant) to MRSA. * Moribund clinical condition such as death likely within the first 3 days of a study drug treatment * History of significant allergy or intolerance to linezolid or BAY1192631 * Known or suspected human immunodeficiency virus (HIV) infection with a CD4+ T-cell count \< 200/μL * Chronic treatment with immunosuppressive drugs * Active tuberculosis or non-tuberculous mycobacteriosis which need medical treatments * Current or anticipated neutropenia with neutrophil count \< 1,000/ mm\^3 * Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \>/= 8 times the upper limit of reference range OR moderate to severe hepatic disease with Child Pugh score \>/=10.